UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics sees analyst downgrade: Guggenheim cuts target price after reassessment, prompting investors to re‑evaluate its kidney‑care drug pipeline.

Unicycive Therapeutics reports Q4 2025 results: a $0.82 per-share loss, narrowing from $2.60 last year, and near‑break‑even full‑year EPS of $1.67.

Unicycive Therapeutics: No new developments or financial updates, only current fundamentals remain unchanged.

Unicycive Therapeutics secures FDA approval to review its oxylanthanum carbonate for hyperphosphatemia—boosting hopes for kidney‑disease treatment and investor growth.

Unicycive Therapeutics wins FDA acceptance for its kidney‑disease drug oxylanthanum carbonate, but an investor probe looms—will the approval spark a share rally or trigger caution?

Unicycive Therapeutics faces volatility as it pursues hyperphosphatemia treatments for kidney disease patients, seeking breakthroughs amid financial uncertainty.

Unicycive Therapeutics resubmits NDA for kidney‑disease hyperphosphatemia therapy; analysts eye $46 target as FDA review moves forward.

Unicycive Therapeutics focuses on developing novel hyperphosphatemia treatments for CKD and AKI, aiming to address unmet kidney disease needs and improve patient outcomes.

Unicycive Therapeutics, a biotech company, has received a Complete Response Letter from the FDA regarding its treatment for hyperphosphatemia, but plans to address manufacturing issues and move forward with its New Drug Application.

Unicycive Therapeutics Inc’s stock plummeted 35% after the FDA flagged significant manufacturing deficiencies at a third-party vendor, casting a shadow over the company’s New Drug Application for a promising kidney disease treatment.